Stockreport

CAPLYTA® (lumateperone) Schizophrenia Safety and Tolerability Profile Published in the Journal, International Clinical Psychopharmacology

Intra-Cellular Therapies Inc.  (ITCI) 
Last intra-cellular therapies inc. earnings: 3/2 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: ir.intracellulartherapies.com/investor-relations
PDF Pooled analysis of 3 randomized, double-blind, pacebo-cotrolled trials supports the safety and the distinct and favorable tolerability profile of lumateperone 42 mg Mea [Read more]